Resources

• Breaking barriers in antibody discovery: Harnessing divergent species for accessing difficult and conserved targets Banik et al. 2023 mAbs 15, 2273018

• Antibody specificity against highly conserved membrane protein Claudin 6 driven by single atomic contact point Screnci et al. 2022 iScience 25, 105665

• Structure and mechanism of blood– brain-barrier lipid transporter MFSD2A Wood et al. 2021 Nature 596, 444-448

• Generating therapeutic monoclonal antibodies to complex multi-spanning membrane targets: Overcoming the antigen challenge and enabling discovery strategies Dodd et al. 2020 Methods 180, 111-126

• Ion channels as therapeutic antibody targets Hutchings et al. 2019 mAbs 11, 265-296

• Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles Tucker et al. 2018 Proceedings of the National Academy of Sciences of the United States of America 115, 4990-4999

• The Bitter Taste Receptor TAS2R16 Achieves High Specificity and Accommodates Diverse Glycoside Ligands by using a Two-faced Binding Pocket Thomas et al. 2017 Scientific Reports 7, 7753-7768

• Discovery of functional mAbs targeting GPCRs and ion channels Wilkinson. 2016 Biochemical Society Transactions 44, 831-837

• Signal transmission through the CXC chemokine receptor 4 (CXCR4) transmembrane helices Wescott et al. 2016 Proceedings of the National Academy of Sciences of the United States of America 113, 9928-9933

• Optimizing Membrane Protein Expression: Improving Surface Expression and Stability for Antibody and Vaccine Discovery Doranz et al. 2015 Genetic Engineering News 35, 15

• A functional comparison of the domestic cat bitter receptors Tas2r38 and Tas2r43 with their human orthologs Sandau et al. 2015 BMC Neuroscience 16, 1-11

• Constitutive activity of an atypical chemokine receptor revealed by inverse agonistic nanobodies Perez Almeria et al. 2025 Nature Communications16, 10828

• TR-FRET between engineered nanobodies reveals the existence of endogenous CXCR4 oligomers Heuninck et al. 2025 Communications Biology 8, 1777

• Multivalent CXCR4-targeting nanobody formats differently affect affinity, receptor clustering, and antagonism Anbuhl et al. 2024 Biochemical Pharmacology 227, 116457

• Structure elucidation of a human melanocortin-4 receptor specific orthosteric nanobody agonist Fontaine et al. 2024 Nature Communications 15, 7029

• Antibody specificity against highly conserved membrane protein claudin 6 driven by single atomic contact point Screnci et al. 2022 iScience 25, 105665

• Structure and mechanism of blood– brain-barrier lipid transporter MFSD2A Wood et al. 2021 Nature 596, 444-448

• D-dopachrome tautomerase contributes to lung epithelial repair via atypical chemokine receptor 3-dependent Akt signaling Song et al. 2021 EBioMedicine 68, 103412

• VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis Low et al. 2020 mAbs 12, 1709322

• Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4 Griffiths et al. 2019 mAbs 11, 1331-1340

• Optimal design, anti-tumour efficacy and tolerability of anti-CXCR4 antibody drug conjugates Costa et al. 2019 Scientific Reports 9, 2443

• Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles Tucker et al. 2018 Proceedings of the National Academy of Sciences of the United States of America 115, 4990-4999

• The constituitive activity of the virally encoded chemokine receptor US28 accelerates glioblastoma growth Heukers et al. 2018 Oncogene 37, 4110-4121

• Anti-fibrotic Effects of CXCR4-Targeting i-body AD-114 in Preclinical Models of Pulmonary Fibrosis Griffiths et al. 2018 Scientific Reports 8, 3212

• DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops Van der Woning et al. 2016 mAbs 8, 1126–1135

• XMT-2056, a HER2-directed STING agonist antibody-drug conjugate, induces innate antitumor immune responses by acting on cancer cells and tumor-resident immune cells Bukhalid et al. 2025 Clinical Cancer Research 31, 1766-1782

• Identification of the Seven Critical Residues that Control ZIKV-DENV Cross-reactivity to Engineer a Non-cross-reactive ZIKV Vaccine Grinyo-Escuer et al. 2025 Cell Reports 44, 116098 

• Redefining antibody patent protection using paratope mapping and CDR-scanning Banik et al. 2025 Nature Biotechnology 43, 170–174

• Anti-Ebola virus mab 3A6 protects highly viremic animals from fatal outcome by binding GP_(1,2) in a position elevated from the virion membrane Hastie et al. 2025 Nature Communications 16, 1293

• A novel class of human ADAM8 inhibitory antibodies for treatment of triple-negative breast cancer Mineva et al. 2024 Pharmaceutics 16, 536

• GNUV201, a novel human/mouse cross-reactive and low pH-selective anti-PD-1 monoclonal antibody for cancer immunotherapy Kim et al. 2024 BMC Immunology 25, 29

• Isolation of human antibodies against influenza B neuraminidase and mechanisms of protection at the airway interface Wolters et al. 2024 Immunity 57, 1413-1427

• Multimodal, broadly neutralizing antibodies against SARS-CoV-2 identified by high-throughput native pairing of BCRs from bulk B cells Keitany et al. 2023 Cell Chemical Biology 30, 1377-1389

• Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes Chen et al. 2023 Cell Reports 42, 112370

• AL008 enhances myeloid antitumor function by inhibiting SIRPa signaling and activating Fc receptors Yang et al. 2023 Journal of Immunology 210, 204-215

• IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2 Nikitin et al. 2022 Science Immunology 7, eabl9943

• Antibody specificity against highly conserved membrane protein claudin 6 driven by single atomic contact point Screnci et al. 2022 iScience 25, 105665

• Broadly neutralizing antibodies target the coronavirus fusion peptide Dacon et al. 2022 Science 377, 728-735

• Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein Suryadevara et al. 2021 Cell 184, 2316-2331

• Functional convergence of a germline-encoded neutralizing antibody response in rhesus macaques immunized with HCV envelope glycoproteins Chen et al. 2021 Immunity 54, 781-796

• Pan-protective anti-alphavirus human antibodies target a conserved E1 protein epitope Kim et al. 2021 Cell 184, 4414-4429

• A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via contextdependent T cell costimulation and checkpoint blockade Geuijen et al. 2021 Nature Communications 12, 4445

• Analysis of a therapeutic antibody cocktail reveals determinants for cooperative and broad ebolavirus neutralization Gilchuk et al. 2020 Immunity 52, 388-403

• Potent ZIKV and DENV cross-neutralizing antibodies induced by Zika vaccination in a DENV-experienced donor Dussupt et al. 2020 Nature Medicine 26, 228-235

• Brain-specific angiogenesis inhibitor 1 is expressed in the Myo/Nog cell lineage Gerhart et al. 2020 PLoS One 15, e0234792

• A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes Davidson and Doranz. 2014 Immunology 143, 13-20

Additional publications by Integral Molecular

• A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants Yang et al. 2024 Antibody Therapeutics 7, 164-176

• Diverse array of neutralizing antibodies elicited upon spike ferritin nanoparticle vaccination in rhesus macaques Sankhala et al. 2024 Nature Communications 15, 200

• Zika-specific neutralizing antibodies targeting inter-dimer envelope epitopes Sankhala et al. 2023 Cell Reports 42, 112942

• Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses Lubow et al. 2023 PLoS Pathogens 19, e1011722

• Targeting the spike receptor binding domain class V cryptic epitope by an antibody with pan-sarbecovirus activity Jensen et al. 2023 Journal of Virology 97, e01596-22

• Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity Chen et al. 2023 Nature Communications 14, 580

• Rare, convergent antibodies targeting the stem helix broadly neutralize diverse betacoronaviruses Dacon et al. 2022 Cell Host & Microbe

• Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress Williamson et al. 2021 Cell 184, 4430-3336

• Somatic Hypermutation and Framework Mutations of Variable Region Contribute to Anti-Zika Virus-Specific Monoclonal Antibody Binding and Function Tsuji et al. 2022 Journal of Virology 96, e00071-22

• Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening Pfaff-Kilgore et al. 2022 Cell Reports 39, 110859

• An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer Suryadevara et al. 2022 Journal of Clinical Investigation 132, e159062

• Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries Yuan et al. 2022 mAbs 14, e2002236

• Exposing cryptic epitopes on the Venezuelan equine encephalitis virus E1 glycoprotein prior to treatment with alphavirus cross-reactive monoclonal antibody allows blockage of replication early in infection Calvert et al. 2022 Virology 565, 13-21

• Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape Ku et al. 2021 Nature Communications 12, 469

• Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals Chen et al. 2021 Cell Reports 36, 109604

• Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition Kramer et al. 2021 Cell Reports 5, 109784

• Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations Dussupt et al. 2021 Nature Immunology 22, 1503-1514

• Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma Gilchuk et al. 2021 Frontiers in Immunology 12, 706757

• An affinity-matured human monoclonal antibody targeting fusion loop epitope of dengue virus with in vivo therapeutic potency Kotaki et al. 2021 Scientific Reports 11, 12987

• A Novel Antigenic Site Spanning Domains I and III of the Zika Virus Envelope Glycoprotein Is the Target of Strongly Neutralizing Human Monoclonal Antibodies Graham et al. 2021 Journal of Virology 95, e02423

• Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies Murin et al. 2021 Cell Reports 35, 108984

• Integrated pipeline for the accelerated discovery of antiviral antibody therapeutics Gilchuk et al. 2020 Nature Biomedical Engineering 4, 1030-1043

• Transcriptional and clonal characterization of B cell plasmablast diversity following primary and secondary natural DENV infection Waickman et al. 2020 EBioMedicine 54, 102733

• Non-neutralizing Antibodies from a Marburg Infection Survivor Mediate Protection by Fc-Effector Functions and by Enhancing Efficacy of Other Antibodies Ilinykh et al. 2020 Cell Host & Microbe 27, 976-991

• Convalescent patient-derived monoclonal antibodies targeting different epitopes of E protein confer protection against Zika virus in a neonatal mouse model Niu et al. 2019 Emerging Microbes & Infections 8, 749-759

• Human antibody response to Zika targets type-specific quaternary structure epitopes Collins et al. 2019 JCI Insight 4, E124588

• Potent neutralizing antibodies elicited by dengue vaccine in rhesus macaque target diverse epitopes Li et al. 2019 PLoS Pathogens 15, E1007716

• Broadly neutralizing human antibodies against dengue virus identified by single B cell transcriptomics Durham et al. 2019 eLife 8, e52384

• Monoclonal antibody 2C6 targets cross-clade conformational epitope in GP41 with highly active antibody dependent cell cytotoxicity Sojar et al. 2019 Journal of Virology 93, e00772

• Broadly Neutralizing Antibodies Targeting New Sites of Vulnerability in Hepatitis C Virus E1E2 Colbert et al. 2019 Journal of Virology 93, e02070

• Early human B cell response to Ebola virus in four U.S. survivors of infection Williamson et al. 2019 Journal of Virology 93, e01439

• Optimal therapeutic activity of monoclonal antibodies against chikungunya virus requires Fc-FcγR interaction on monocytes Fox et al. 2019 Science Immunology 4, eaav5062

• Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitope Long et al. 2019 Proceedings of the National Academy of Sciences of the United States of America 116, 1591-1596

• Increased breadth of HIV-1 neutralization achieved by diverse antibody clones each with limited neutralization breadth Chukwuma et al. 2018 PLoS One 13, E0209437

• Broadly neutralizing antibody mediated clearance of human hepatitis C virus infection Kinchen et al. 2018 Cell Host & Microbe 24, 717-730

• In vivo delivery of synthetic human DNA-encoded monoclonal antibodies protect against ebolavirus infection in a mouse model Patel et al. 2018 Cell Reports 25, 1982-1993

• Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection Saphire et al. 2018 Cell 174, 938-952

• Multifunctional pan-ebolavirus antibody recognizes a site of broad vulnerability on the ebolavirus glycoprotein Gilchuk et al. 2018 Immunity 49, 363-374

• Mxra8 is a receptor for multiple arthritogenic alphaviruses Zhang et al. 2018 Nature 557, 570-574

• Human antibody recognition of antigenic site IV on Pneumovirus fusion proteins Mousa et al. 2018 PLoS Pathogens 14, e1006837

• Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2–MPER region Flyak et al. Nature Microbiology 3, 670-677

• High-throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers Sullivan et al. 2017 Journal of Virology 91, E00862

• Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis Gopal et al. 2017 PLoS Pathogens 13, E1006735

• Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability Zhao et al. 2017 Cell 169, 891-904

• Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus Howell et al. 2017 Cell Reports 19, 413-424

• Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance Bailey et al. 2017 JCI Insights 2, E92872

• A Biologically-validated HCV E1E2 Heterodimer Structural Model Castelli et al. 2017 Scientific Reports 7, 214-227

• Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination Nivarthi et al. 2017 Journal of Virology 91, E02041

• How to turn competitors into collaborators Saphire at al. 2017 Nature 541, 283-285

• Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis Jin et al. 2016 Cell Reports 13, 2553-2564

• Protective Capacity of the Human Anamnestic Antibody Response during Acute Dengue Virus Infection Xu et al. 2016 Journal of Virology 90, 11122-11131

• Rapid isolation of dengue-neutralizing antibodies from single cell-sorted human antigen-specific memory B-cell cultures Cox et al. 2016 mAbs 8, 129-140

• Integral Molecular Sizes Up Ebola: Membrane Protein Specialist Maps Ebola’s Binding Sites to Advance Vaccine Discovery Dutton. 2016 Genetic Engineering News 36, 1

• Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein Mousa et al. 2016 Proceedings of the National Academy of Sciences of the United States of America 113, E6849–E6858

• Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice Sapparapu et al. 2016 Nature 540, 443–447

• Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein Hicar et al. 2016 PLoS One 11, E0158861

• Dengue Virus prM-Specific Human Monoclonal Antibodies with Virus Replication-Enhancing Properties Recognize a Single Immunodominant Antigenic Site Smith et al. 2016 Journal of Virology 90, 780-789

• Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site Howell et al. 2016 Cell Reports 15, 1514-26

• Lower IgG somatic hypermutation rates during acute dengue virus infection is compatible with a germinal center-independent B cell response Godoy-Lozano et al. 2016 Genome Medicine 8, 23

• Cross-Reactive and Potent Neutralizing Antibody Responses in Human Survivors of Natural Ebolavirus Infection Flyak et al. 2016 Cell 164, 392-405

• Mechanism of Binding to Ebola Virus Glycoprotein by the ZMapp, ZMAb, and MB-003 Cocktail Antibodies Davidson et al. 2015 Journal of Virology 89, 10982-10992

• Cryo-EM structures Elucidate Neutralizing Mechanisms of anti-Chikungunya Human Monoclonal Antibodies with Therapeutic Activity Long et al. 2015 Proceedings of the National Academy of Sciences of the United States of America 112, 13898-13903

• Preclinical evaluation of antigen-specific B-cell depletion for phospholipase A2 receptor membranous nephropathy with chimeric autoantibody receptor T cells Altun et al 2026 Kidney International 109, 89-100

• MUC18-directed chimeric antigen receptor T cells for the treatment of mucosal melanoma Zhang et al 2025 Journal of Translational Medicine 23, 473

• First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumors Staquicini et al 2025 The Journal of Clinical Investigation 135, 188492

• Preclinical development and a phase 1 trial of IMC001, an EpCAM-targeted CAR-T cell therapy, in patients with advanced gastric cancer Fang et al 2025 Molecular Therapy 33, 5516-5529

• Preclinical development of T cells engineered to express a T-cell antigen coupler targeting Claudin 18.2–positive solid tumors Xu et al. 2025 Cancer Immunology Research 13, 35-46

• A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells Zhang et al. 2025 Frontiers in Immunology 15, 1531294

• The emergence of cell-based protein arrays to test for polyspecific off-target binding of antibody therapeutics Norden et al. 2024 mAbs 16, 1

• Discovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer Chu et al. 2024 mAbs 16, 1

• Identification of a fully human antibody VH domain targeting anaplastic lymphoma kinase (ALK) with applications in ALK-positive solid tumor immunotherapy Chen et al. 2024 antibodies 13, 39

• Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate Sun et al. 2023 Molecular Therapy Oncology 31, 100726

• Novel anti-CD30/CD3 bispecific antibodies activate human T cells and mediate anti-tumor activity Faber et al. 2023 Frontiers in Immunology 14, 1225610

• Preclinical safety and efficacy of a therapeutic antibody that targets SARS-CoV-2 at the sotrovimab face but is escaped by omicron Kreye et al. 2023 iScience 26, 106323

• Human antibodies targeting ENPP1 as candidate therapeutics for cancers Chu et al. 2023 Frontiers in Immunology 14, 1070492

• B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukemia Fan et al. 2023 European Journal of Medical Research 28, 129

• Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells Oh et al. 2023 Nature Biotechnology

• The third-generation anti-CD30 CAR T-cells specifically homing to the tumor and mediating powerful antitumor activity Zhang et al. 2022 Scientific Reports 12, 10488

• Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma Qu et al. 2022 Journal of Immunotherapy for Cancer 10, e005145

• GPC2-CAR T cells tuned for low antigen density mediate potent activity against neuroblastoma without toxicity Heitzeneder et al. 2022 Cancer Cell 40, 53-69

• Testing for Off-target Binding Norden and Doranz. 2021 Translational Medicine: Optimizing Preclinical Safety Evaluation of Biopharmaceuticals

• A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL Tan et al. 2021 Blood Cancer Journal 11, 71

• Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4 Bhoj et al. 2021 Molecular Therapy Oncolytics 20, 387-398

• Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris Lee et al. 2020 Journal of Clinical Investigation 130, 6317-6324

• High Potency of a Bivalent Human VH Domain in SARS-CoV-2 Animal Models Li et al. 2020 Cell 183, 429-441

• Screening the Membrane Proteome- A High-Throughput Platform for Identifying Membrane Protein Antibody Targets Huston-Paterson et al. 2016 Genetic Engineering News 36, 15

• For Virology publications, visit the Virology at Integral Molecular Resources page.